Mechanisms of action of anti-inflammatory medications used for the treatment of osteoarthritis

Journal of the American Veterinary Medical Association

Volumn 210, Issue 10, 1997, Pages 1486-1492

  Johnston, Spencer A ^a,b   Fox, Steven M ^c  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CORTICOSTEROID; IBUPROFEN; INDOMETACIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PREDNISOLONE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SALICYLIC ACID DERIVATIVE; TENIDAP; TRIAMCINOLONE;

ANTIINFLAMMATORY ACTIVITY; DOG; DRUG MECHANISM; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; REVIEW; SHEEP; STOMACH DISEASE;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DOG DISEASES; DOGS; GASTRIC MUCOSA; KIDNEY; KIDNEY DISEASES; NITRIC OXIDE; OSTEOARTHRITIS; STOMACH ULCER;

EID: 0030988349     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Clements PJ, Paulus HE. Nonsteroidal anti-inflammatory drugs (NSAIDs). In: Kelley WN, Harris ED, Ruddy S, et al, eds. Textbook of rheumatology. 4th ed. Philadelphia: WB Saunders Co, 1993;700-730.
2. Wittenberg RH, Willburger RE, Kleemeyer KS, et al. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 1993;10:1444-1450.
3. Pelletier JP, DiBattista JA, Roughley P, et al. Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am 1993;19:545-568.
4. Levine JD, Taiwo YO. Hyperalgesic pain: a review. Anesth Prog 1990;37:133-135.
5. Bhoola KD. Kinins - key mediators in inflammatory arthritis? Br J Rheumatol 1992;31:509-518.
6. Ferreira SH. Prostaglandins, aspirin-like drugs, and analgesia. Nature 1972;240:200-203.
7. Jessell TM, Kelly DD. Pain and analgesia. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principles of neural science. 3rd ed. Norwalk, Conn: Appleton & Lange, 1991;385-399.
8. Fields HL. Pain. New York: McGraw-Hill Book Co, 1987;28-38.
9. 4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 1984;225:743-745.
10. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature (London) New Biol 1971;231:232-235.
11. Mankin HJ, Conger KA. The acute effects of intra-articular hydrocortisone on articular cartilage in rabbits. J Bone Joint Surg Am 1966;48:1383-1388.
12. Behrens F, Shepard N, Mitchell N. Alterations of rabbit articular cartilage by intra-articular injections of glucocorticoids. J Bone Joint Surg Am 1975;57:70-76.
13. Chunekamrai S, Krook LP, Lust G, et al. Changes in articular cartilage after intra-articular injections of methylprednisolone acetate in horses. Am J Vet Res 1989;50:1733-1741.
14. Pelletier JP, Martel-Pelletier J. Cartilage degradation by neutral proteoglycanases in experimental osteoarthritis: suppression by steroids. Arthritis Rheum 1985;28:1393-1401.
15. Pelletier JP, DiBattista JA, Raynauld JP, et al. The in vivo effects of intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1, and oncogene protein synthesis in experimental osteoarthritis. Lab Invest 1995;72:578-586.
16. Pelletier JP, Martel-Pelletier J. Protective effects of corticosteroids on cartilage lesions and osteophyte formation in the Pond-Nuki model of osteoarthritis. Arthritis Rheum 1989;32:181-193.
17. Shoemaker RS, Bertone AL, Martin GS, et al. Effects of intra-articular administration of methylprednisolone acetate on normal articular cartilage and on healing of experimentally induced osteochondral defects in horses. Am J Vet Res 1992;53:1446-1453.
18. Carter BG, Bertone AL, Weisbrode SE, et al. Influence of methylprednisolone acetate on osteochondral healing in exercised tarsocrural joints of horses. Am J Vet Res 1996;57:914-922.
19. Brandt KD. Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo. Am J Med 1987;53(Suppl 5A):29-34.
20. Palmoski MJ, Brandt KD. Effect of salicylate on proteoglycan metabolism in normal canine articular cartilage in vitro. Arthritis Rheum 1979;22:746-754.
21. Shield MJ. Misoprostol: new frontiers; benefits beyond the gastrointestinal tract. Scand J Rheumatol Suppl 1992;92:31-52.
22. Palmoski MJ, Brandt KD. In vivo effect of aspirin on canine osteoarthritic cartilage. Arthritis Rheum 1983;26:994-1001.
23. Palmoski MJ, Brandt KD. Aspirin aggravates the degeneration of canine joint cartilage caused by immobilization. Arthritis Rheum 1982;25:1333.
24. Schnitzer TJ. Management of osteoarthritis. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. 12th ed. Philadelphia: Lea & Febiger, 1993;1761-1769.
25. Diaz-Gonzalez F, Gonzalez-Alvaro I, Companero MR, et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest 1995;95:1756-1765.
26. Abramson SB, Weissmann G. The mechanism of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989;32:1-9.
27. Vignon E, Mathieu P, Louisot P, et al. In vitro effect of nonsteroidal antiinflammatory drugs on proteoglycanase and collagenase activity in human osteoarthritic cartilage. Arthritis Rheum 1991;34:1332-1335.
28. Furst DE, Paulus HE. Aspirin and other nonsteroidal antiinflammatory drugs. In: McCarty DJ, Koopman WJ, eds. Arthritis and allied conditions. 12th ed. Philadelphia: Lea & Febiger, 1993;567-602.
29. Ratcliffe A, Rosenwasser MP, Mahmud F, et al. The in vivo effects of naproxen on canine experimental osteoarthritic articular cartilage: composition, metalloproteinase activities and metabolism. Agents Actions Suppl 1993;39:207-211.
30. Pelletier JP, Cloutier JM, Martel-Pelletier J. In vitro effects of NSAIDs and corticosteroids on the synthesis and secretion of interleukin 1 by human osteoarthritic synovial membranes. Agents Actions Suppl 1993;39:181-193.
31. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:2017-2019.
32. Dawson W, Boot JR, Harvey J, et al. The pharmacology of benoxaprofen with particular reference to effects on lipoxygenase product formation. Eur J Rheumatol Inflamm 1982;5:61-68.
33. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991;324:1716-1725.
34. May SA, Lees P. Nonsteroidal anti-inflammatory drugs In: McIlwraith CW, Trotter GW, eds. Joint disease in the horse. Philadelphia: WB Saunders Co, 1996;223-237.
35. Kujubu DA, Fletcher BS, Varnum BC, et al. TIS 10, a phorbol ester tumor promoter inducible mRNA from Swiss 3t3 cells, encodes a novel prostaglandin synthase/cyclo-oxygenase homologue. J Biol Chem 1991;266:12866-12872.
36. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-2696.
37. Xie W, Robertson DL, Simmons DL. Mitogen-induced prostaglandin G/H synthase: a novel target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992;25:249-265.
38. Frolich JC. Prostaglandin endoperoxide synthetase isoenzymes: the clinical relevance of selective inhibition. Ann Rheum Dis 1995;54:942-943.
39. Mitchell JA, Larkin S, Williams TJ. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol 1995;50:1535-1542.
40. Masferrer JL, Seibert K, Zweifel B, et al. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992;89:3917-3921.
41. Vane JR, Botting RM. A better understanding of antiinflammatory drugs based on isoforms of cyclooxygenase (COX-1 and COX-2). Adv Prostaglandin Thromboxane Leukot Res 1995;23:41-48.
42. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-11697.
43. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-934.
44. Engelhardt G, Bogel R, Schnitzer C, et al. Meloxican(sic): influence on arachidonic acid metabolism. Part 1: in vitro findings. Biochem Pharmacol 1996;51:21-28.
45. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-796.
46. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993;88:1318-1323.
47. Wallace JL. Mechanisms of nonsteroidal anti-inflammatory drug (NSAID) induced gastrointestinal damage-potential for development of gastrointestinal tract safe NSAIDs. Can J Physiol Pharmacol 1994;72:1493-1498.
48. Fries JF, Williams CA, Bloch DA. The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1991;34:1353-1360.
49. Vane JR. NSAIDs, COX-2 inhibitors, and the gut (lett). Lancet 1995;346:1105-1106.
50. 2 synthases. Chem Biol Interact 1995;2:343-350.
51. Sipe JD. Acute-phase proteins in osteoarthritis. Semin Arthritis Rheum 1995;25:75-86.
52. Fernandes JC, Martel-Pelletier J, Otterness IG, et al. Effects of tenidap on canine experimental osteoarthritis: I. Morphologic and metalloprotease analysis. Arthritis Rheum 1995;38:1290-1303.
53. Richardson CE, Emery P. New cyclo-oxygenase and cytokine inhibitors. Baillieres Clin Rheumatol 1995;9:731-758.
54. Johnston SA, Leib MS, Forrester SD. The effect of misoprostol on aspirin-induced gastroduodenal lesions in dogs. J Vet Intern Med 1995;9:32-38.
55. Vasseur PB, Johnson AL, Budsberg SC, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal antiinflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995;206:807-811.
56. Budsberg S, Johnston S, Schwarz P, et al. Evaluation of etodolac for the treatment of osteoarthritis of the hip in dogs: a prospective multicenter study. Vet Surg 1996;25:420-421.
57. Cross AR, Budsberg SC. Use of ground reaction forces in the evaluation of the efficacy of meloxicam in the moderation of hindlimb lameness with induced, acute stifle synovitis, in Proceedings. Br Small Anim Vet Soc Annu Congr, 1996;208.
58. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994;37:1-9.
59. Frey HH, Rieh B. Pharmacokinetics of naproxen in the dog. Am J Vet Res 1981;42:1615-1617.
60. Konturek SJ, Konturek JW. Gastric adaptation: basic and clinical aspects. Digestion 1994;55:131-138.
61. Kaufmann G. Aspirin-induced gastric mucosal injury: lessons learned from animal models. Gastroenterology 1989;96:606-614.
62. Miller TA. Gastroduodenal mucosal defense: factors responsible for the ability of the stomach and duodenum to resist injury. Surgery 1988;103:389-397.
63. Scheiman JM. NSAID-induced peptic ulcer disease: a critical review of pathogenesis and management. Dig Dis 1994;12:210-222.
64. Sant SM, Cahill RJ, Gilvarry J, et al. Do non-steroidal anti-inflammatory drugs have an effect on gastric cell turnover? Aliment Pharmacol Ther 1995;9:575-579.
65. Wallace JL. Gastric ulceration: critical events at the neutrophil-endothelium interface. Can J Physiol Pharmacol 1993;71:98-102.
66. McCafferty DM, Granger DN, Wallace JL. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology 1995;109:1173-1180.
67. 1 (misoprostol) for prevention of aspirin-induced gastroduodenal ulceration in arthritic dogs. J Am Vet Med Assoc 1993;202:251-256.
68. Dingle JT. Cartilage maintenance in osteoarthritis: interaction of cytokines, NSAID and prostaglandins in articular cartilage damage and repair. J Rheumatol Suppl 1991;18:30-37.
69. Rainsford KD. Mechanisms of NSAIDs on joint destruction in osteoarthritis. Agents Actions Suppl 1993;44:39-43.
70. Piweucci A, Patrono C. NSAIDs in renal impairment and dialysis. In: Famaey JP, Paulus HE, eds. Therapeutic applications of NSAIDs. New York: Marcel Dekker Inc. 1992;211-246.
71. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996;28(Suppl 1):S56-S62.
72. Rubin SI. Nonsteroidal antiinflammatory drugs, prostaglandins, and the kidney. J Am Vet Med Assoc 1986;188:1065-1068.
73. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-572.
74. Ailabouni W, Eknoyan G. Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly. Drugs Aging 1996;9:341-351.
75. Segasothy M, Samad SA, Zulfigar A, et al. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 1994;24:17-24.
76. Barrett BJ. Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Am J Kidney Dis 1996;28(Suppl 1):S14-S19.
77. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994;331:1675-1679.
78. D'Agati V. Does aspirin cause acute or chronic renal failure in experimental animals and humans? Am J Kidney Dis 1996;28 (Suppl 1):S24-S29.
79. Sandler DP, Burr R, Weinberg CR. Nonsteroidal antiinflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991;115:165-172.
80. Blantz RC. Acetaminophen: acute and chronic effects on renal function. Am J Kidney Dis 1996;28(Suppl 1):S3-S6.
81. Urquhart E. Central analgesic activity of nonsteroidal antiinflammatory drugs in animal and human pain models. Semin Arthritis Rheum 1993;23:198-205, 70.
82. McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994;59:9-43.
83. Bannwarth B, Demotes-Mainard F, Schaeverbeke T, et al. Where are peripheral analgesics acting? Ann Rheum Dis 1993;52:1-4.
84. Day RO. Aspirin and salicylates. In: Kelley WN, Harris ED, Ruddy S, et al, eds. Textbook of rheumatology. 4th ed. Philadelphia: WB Saunders Co, 1993;681-691.
85. Bradley JD, Brandt KD, Katz BP. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991;325:87-91.
86. Williams JH, Ward JR, Egger MJ. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;36:1196-1206.
87. March L, Irwig L, Schwarz J. n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ 1994;309:1041-1045.
88. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012.
89. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994;343:1199-1206.
90. Wu KK. Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 1995;33:179-207.
91. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and NO synthase in inflammation. Proc Natl Acad Sci U S A 1994;91:2046-2050.
92. Salvemini D, Manning PT, Zweifel BS, et al. Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J Clin Invest 1995;96:301-308.
93. Amin AR, DiCesare PE, Vyas P, et al. The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for up regulated neuronal nitric oxide synthase. J Exp Med 1995;182:2097-2102.
94. Stefanovic-Racic M, Stadler J, Evans CH. Nitric oxide and arthritis. Arthritis Rheum 1993;36:8.
95. Amin AR, Vyas P, Attur M, et al. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci U S A 1995;92:7926-7930.
96. Aeberhard EE, Henderson SA, Arabolos NS, et al. Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene. Biochem Biophys Res Commun 1995;208:1053-1059.
97. Arndt H, Russell JB, Kurose I, et al. Mediators of leukocyte adhesion in rat mesenteric venules elicited by inhibition of nitric oxide synthesis. Gastroenterology 1993;105:675-680.
98. Wallace JL, Reuter BK, Cirino G. Nitric oxide-releasing non-steroidal anti-inflammatory drugs: a novel approach for reducing gastrointestinal toxicity. J Gastroenterol Hepatol 1994;9:S40-S44.
99. Elliott SN, McKnight W, Cirino G, et al. A nitric oxide-releasing anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995;109:524-530.
100. Wallace JL, Reuter B, Cicala C, et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994;107:173-179.
101. Marriotto S, Menegazzi M, Carcereri de Prati A, et al. Protective effect of NO on gastric lesions and inhibition of expression of gastric inducible NOS by flurbiprofen and its nitro-derivitive, nitroflurbiprofen. Br J Pharmacol 1995;116:1713-1714.
102. Zinn WJ. Aspirin: tiger or pussy cat. Ear Nose Throat J 1996;75:200-207.